Other Information.
−Removed: Akebia Therapeutics, Inc.
−Removed: | Form 10-Q | Page 97
Rule 10b5-1—Director and Officer Trading Arrangements
10 unchanged sentences
3.3 Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (001-36352), filed on April 28, 2023).
−Removed: Termination and Settlement Agreement, dated July 10, 2024, by and between the Company and Vifor (International) Ltd.
−Removed: (incorporated by reference to Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q (001-36352), filed on August 8, 2024).
−Removed: Amendment #1 to Agreement for the Provision of a Loan Facility, dated July 10, 2024, by and between the Company and Kreos Capital VII (UK) Limited (incorporated by reference to Exhibit 10.
−Removed: 5 to the Company's Quarterly Report on Form 10-Q (001-36352), filed on August 8, 2024).
−Removed: Amended and Restated Open Market Sale Agreement, dated September 3, 2024, by and between the C ompany and Jefferies LLC (incorporated by reference to Exhibit 1.2 to the Company's Registration S tatement on Form S-3 (333-281903) f iled on Septem ber 3, 202 4).
−Removed: A mendment #1 to License Agreement, dated August 30 , 202 4 , by and among Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc.
−Removed: and Averoa SA S .
−Removed: A mendment #1 to Supply Agreement, dated Oc tober 15, 202 4, by and between the Company and STA Pharmaceutical Hong Kong Limited .
+Added: F orm of Warrant (incorporated by reference to Exhibit 4.7 to the Com pany's Annual Report on Form 10-K (000-3 6352) , filed on March 14, 202 4 ) .
+Added: Fourth Amended and Restated Non-Employee Director Compensation Program, effective January 27, 2025 (incorporated by reference to Exhibit 10.18 to the Company's Annual Report on Form 10-K (000-36352) , filed on March 13, 2025 ) .
+Added: S econd Amendment to Agreement for the Provision of a Loan Facility, dated February 3, 2025, by and between Akebia Therapeutics, Inc.
+Added: and Kreos Capital VII (UK) Limited (incorporated by reference to Exhibit 10.105 to the Co mpany's Annual Report on Form 10-K (000-36352 ), filed on March 13, 2025 ) .
31.1* Certification of Principal Executive Officer Required Under Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended.
14 unchanged sentences
AKEBIA THERAPEUTICS, INC.
−Removed: November 7, 2024
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: November 7, 2024
Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer
(Principal Financial Officer)
−Removed: November 7, 2024
/s/ Richard C.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.